Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration
Neurobiology of Aging: age-related phenomena, neurodegeneration and neuropathology , Volume 30 - Issue 4 p. 656- 665
Frontotemporal lobar degeneration (FTLD) is now recognised as a common form of early onset dementia. Up to 40% of patients have a family history of disease demonstrating a large genetic component to its etiology. Linkage to chromosome 9p21 has recently been reported in families with this disorder. We undertook a large scale two-stage linkage disequilibrium mapping approach of this region in the Manchester FTLD cohort. We identified association of ubiquitin associated protein 1 (UBAP1; OR 1.42 95% CI 1.08-1.88, P = 0.013) with FTLD in this cohort and we replicated this finding in an additional two independent cohorts from the Netherlands (OR 1.33 95% CI 1.04-1.69, P = 0.022), the USA (OR 1.4 95% CI 1.02-1.92, P = 0.032) and a forth Spanish cohort approached significant association (OR 1.45 95% CI 0.97-2.17, P = 0.064). However, we failed to replicate in a fifth cohort from London (OR 0.99 95% CI 0.72-1.37, P = 0.989). Quantitative analysis of UBAP1 mRNA extracted from tissue from the Manchester cases demonstrated a significant reduction of expression from the disease-associated haplotype. In addition, we identified a case of familial FTLD that demonstrated colocalisation of UBAP1 and TDP-43 in the neuronal cytoplasmic inclusions in the brain of this individual. Our data for the first time identifies UBAP1 as a genetic risk factor for FTLD and suggests a mechanistic relationship between this protein and TDP-43.
|, , , ,|
|Neurobiology of Aging: age-related phenomena, neurodegeneration and neuropathology|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Rollinson, S, Rizzu, P, Sikkink, S, Baker, M.C, Halliwell, N, Snowden, J, … Pickering-Brown, S. (2009). Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration. Neurobiology of Aging: age-related phenomena, neurodegeneration and neuropathology, 30(4), 656–665. doi:10.1016/j.neurobiolaging.2009.01.009